Testing a new cancer treatment for advanced lung cancer

Plain-English translation of NCT07638891 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated August 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This clinical trial is testing a new medication called HDM2020 to see if it is safe and effective for treating advanced squamous non-small cell lung cancer in patients whose tumors have specific genetic markers (FGFR2 expression). The trial will enroll up to 150 patients whose cancer has progressed despite previous standard treatments like chemotherapy and immunotherapy. Researchers want to understand how well this medication works and what side effects patients might experience.

Advanced squamous lung cancer is difficult to treat, especially for patients whose cancers have stopped responding to standard chemotherapy and immunotherapy. This trial exists to explore whether this new treatment can help patients with this hard-to-treat cancer type, particularly those whose tumors have specific genetic characteristics that might make them responsive to this medication.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced squamous non-small cell lung cancer (stage 3B, 3C, or stage 4) that cannot be treated with surgery
your cancer has progressed or you did not tolerate previous standard treatments, including platinum-based chemotherapy and immunotherapy drugs
your tumor has been tested and shows high FGFR2b expression (a specific genetic marker)
you are between 18 and 75 years old and in reasonably good overall health
you are able to attend regular clinic visits and follow study procedures
your expected survival is longer than 3 months

You likely don't qualify if…

you have previously received a similar cancer drug (an antibody-drug conjugate with a topoisomerase I inhibitor)
you have current or chronic corneal (eye) problems, including corneal inflammation, ulcers, or a history of corneal transplant
you had major surgery within the past 4 weeks or extensive radiation therapy within the past 4 weeks
you are unwilling or unable to use contraception for 7 months after your last dose of the medication
your organs (liver, kidneys, heart, bone marrow) are not functioning well enough for the trial

What participation looks like

If you join this trial, you will receive the medication HDM2020 as an intravenous infusion (through an IV in your arm). You will need to visit the clinic regularly for treatment, blood tests, imaging scans, and monitoring to check how the medication is working and what side effects you might be experiencing. The study will track your health throughout the treatment period and for several months afterward to ensure your safety.

AI-generated summary from trial data · Aug 29, 2026 · Not medical advice

Trial locations(1 site)

China

Guangdong Provincial People's Hospital, Guangzhou, Guangdong